Lampalizumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameLampalizumab
Drug Alias Name兰帕组单抗Anti-factor DAnti-complement Factor D antibody兰帕利珠单抗Anti-factor D Fab +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement factor D inhibitorsImmunomodulators
TargetsComplement factor D
Therapy Area/IndicationsGeographic Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche LtdGenentech Inc
Active IndicationsN/A
Inactive IndicationsGeographic Atrophy

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG